GLOW
Also called GHK-Cu + BPC-157 + TB-500
No single human route established in this referenceEvidence gap
Research reference
Evidence gap
GLOW blend evidence gap
No source-backed schedule
No established human course
When results may show
GLOW
Evidence gap- When change was measured
- No measured human outcome window identified for this exact material.
- When to assess
- No established human course
- Conditions and limitations
- No exact-product primary protocol located in this review. No exact-blend primary protocol was located. Individual ingredients do not establish a combined dose, mixing stability or course.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
No direct outcome source identified. See the compound page for evidence grading.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
What is in a 70 mg GLOW vial
| Component | Share | Per vial |
|---|---|---|
| GHK-Cu | 71% | 50 mg |
| BPC-157 | 14% | 10 mg |
| TB-500 | 14% | 10 mg |
Every draw has these same proportions.
Modelled level — every day
One curve per component: the components clear at very different rates.
GHK-Cu (in GLOW)BPC-157 (in GLOW)TB-500 (in GLOW)